Company: ARWR
Filing Date: 2025-10-10
Form Type: 10-K/A
Source: 0000879407-25-000013
Chunk: 30

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-10-10
Form: 10-K/A
Chunk 30
---
 new drug candidates                                                                                                                                                                                          |

Annual Incentive Award Payments

The actual annual cash incentive award payments earned by our incumbent NEOs totaled 127% of the respective target award opportunities. Except for the annual incentive award for our CEO, these awards were recommended by our CEO and approved by the Compensation Committee based on the overall achievement of our goals, their contributions to the goals and the overall performance of each executive officer during the year. The following table sets forth the target annual cash incentive award opportunities, the target award expressed as a percentage of each NEO’s base salary and the actual award payment made in cash or cash equivalents to each of our NEOs based on their performance in fiscal 2024:

| Named Executive       
 Officer               |     | Target AnnualIncentive AwardOpportunity (as apercentage of  basesalary) |     | Achievement target bonus |     | Actual AnnualIncentive Award($) |     |            |
| Dr. Anzalone (1)      |     | 100%                                                                    |     | 120%                     |     |                                 |     | $1,152,000 |
| Mr. Myszkowski        |     | 45%                                                                     |     | 120%                     |     |                                 |     |   $314,496 |
| Mr. O’Brien           |     | 45%                                                                     |     | 140%                     |     |                                 |     |   $378,000 |
| Dr. Hamilton          |     | 45%                                                                     |     | 120%                     |     |                                 |     |   $314,496 |
| Dr. San Martin (2)    |     | 45%                                                                     |     | —%                       |     | $—                              |     |            |
| Ms. Tracie Oliver (3) |     | 40%                                                                     |     | —%                       |     | $—                              |     |            |

(1) Dr. Anzalone received an initial bonus of $960,000, which was paid in December 2024 and an additional bonus of $192,000 which will be paid upon receipt of Hart Scott Rodino clearance of the Sarepta transaction.

(2) Dr. San Martin left the Company on February 1, 2024 and did not receive an annual incentive award.

(3) Ms. Oliver served as the Company's Chief Commercial Officer until October 2024 and did not receive an annual incentive award.

The annual cash incentive award payments made to our NEOs for fiscal